Keeping Track: Two Novel Migraine Drugs Highlight Busy Week For US FDA Approvals
The latest drug development news and highlights from our US FDA Performance Tracker.
You may also be interested in...
The latest decision by the health technology assessment body means up to 10,000 people will be able to receive Teva’s drug on the National Health Service. Ajovy is the first anti-CGRP migraine therapy recommended by NICE, whose decision will also be of interest to CGRP inhibitor rivals including Novartis, Lilly and Lundbeck.
The fast-dissolving tablet will launch in early March. Its list price is not available but based on pricing for Allergan’s oral anti-CGRP Ubrelvy, ICER has said Biohaven’s rimegepant is likely to be cost-effective.
After eptinezumab’s approval in the US, EVP Peter Anastasiou told Scrip it will take time to change migraine doctors’ prescribing habits, but he expects CGRP inhibitors to become mainstay preventative treatments. Vyepti’s list price is about $1,000 below its competitors’ launch prices.